Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy

Journal of Lipid Research

Volumn 55, Issue 3, 2014, Pages 561-572

  Herman Edelstein, Michal ^a   Scherzer, Pnina ^b,c   Tobar, Ana ^a   Levi, Moshe ^d,e   Gafter, Uzi ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c JERUSALEM COLLEGE OF ENGINEERING   (Israel)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cholesterol metabolism; Lipid droplets; Lipotoxicity

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ACYL COENZYME A OXIDASE; APOLIPOPROTEIN E; CARNITINE PALMITOYLTRANSFERASE I; CHOLESTEROL; FATTY ACID BINDING PROTEIN; LIPID; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; FATTY ACID OXIDATION; FEMALE; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; INFLAMMATION; KIDNEY BIOPSY; KIDNEY METABOLISM; LIPID METABOLISM; LIPID STORAGE; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CHOLESTEROL METABOLISM; LIPID DROPLETS; LIPOTOXICITY;

ADULT; AGED; ANTIGENS, CD36; ATP BINDING CASSETTE TRANSPORTER 1; CHOLESTEROL; DIABETIC NEPHROPATHIES; DIACYLGLYCEROL O-ACYLTRANSFERASE; FATTY ACID-BINDING PROTEINS; FATTY ACIDS; FEMALE; GENE EXPRESSION; HUMANS; KIDNEY; LIPID METABOLISM; LIPIDS; LIPOGENESIS; MALE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON; MIDDLE AGED; PPAR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIGLYCERIDES;

EID: 84894847603     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P040501     Document Type: Article

References (50)

1. Rutledge, J. C., K. F. Ng, H. H. Aung, and D. W. Wilson. 2010. Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat. Rev. Nephrol. 6: 361-370.
2. Cooper, M. E., and K. A. Jandeleit-Dahm. 2005. Lipids and diabetic renal disease. Curr. Diab. Rep. 5: 445-448. (Pubitemid 43020011)
3. Schulze, P. C. 2009. Myocardial lipid accumulation and lipotoxicity in heart failure. J. Lipid Res. 50: 2137-2138.
4. Li, W. Y., C. X. Yao, S. F. Zhang, S. L. Wang, T. Q. Wang, C. J. Xiong, Y. B. Li, and M. X. Zang. 2012. Improvement of myocardial lipid accumulation and prevention of PGC-1α induction by fenofibrate. Mol. Med. Rep. 5: 1396-1400.
5. Marfella, R., C. Di Filippo, M. Portoghese, M. Barbieri, F. Ferraraccio, M. Siniscalchi, F. Cacciapuoti, F. Rossi, M. D'Amico, and G. Paolisso. 2009. Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome. J. Lipid Res. 50: 2314-2323.
6. Sharma, S., J. V. Adrogue, L. Golfman, I. Uray, J. Lemm, K. Youker, G. P. Noon, O. H. Frazier, and H. Taegtmeyer. 2004. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 18: 1692-1700. (Pubitemid 39463708)
7. Proctor, G., T. Jiang, M. Iwahashi, Z. Wang, J. Li, and M. Levi. 2006. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes. 55: 2502-2509. (Pubitemid 44871150)
8. Kim, H. J., H. Moradi, J. Yuan, K. Norris, and N. D. Vaziri. 2009. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am. J. Physiol. Renal Physiol. 296: F1297-F1306.
9. Bobulescu, I. A. 2010. Renal lipid metabolism and lipotoxicity. Curr. Opin. Nephrol. Hypertens. 19: 393-402.
10. Jiang, T., X. X. Wang, P. Scherzer, P. Wilson, J. Tallman, H. Takahashi, J. Li, M. Iwahashi, E. Sutherland, L. Arend, et al. 2007. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes. 56: 2485-2493. (Pubitemid 47523255)
11. Wang, X. X., T. Jiang, Y. Shen, L. Adorini, M. Pruzanski, F. J. Gonzalez, P. Scherzer, L. Lewis, S. Miyazaki-Anzai, and M. Levi. 2009. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am. J. Physiol. Renal Physiol. 297: F1587-F1596.
12. Gröne, H. J. 1999. Glomerular lipids in non-hereditary forms of glomerulopathy/glomerulonephritis. Nephrol. Dial. Transplant. 14: 1595-1598.
13. Kamanna, V. S., D. D. Roh, and M. A. Kirschenbaum. 1998. Hyperlipidemia and kidney disease: concepts derived from histopathology and cell biology of the glomerulus. Histol. Histopathol. 13: 169-179. (Pubitemid 28044610)
14. Herman-Edelstein, M., M. C. Thomas, V. Thallas-Bonke, M. Saleem, M. E. Cooper, and P. Kantharidis. 2011. Dedifferentiation of immortalized human podocytes in response to transforming growth factor-β: a model for diabetic podocytopathy. Diabetes. 60: 1779-1788.
15. Nosadini, R., and G. Tonolo. 2011. Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 21: 79-85.
16. Wang, Z., T. Jiang, J. Li, G. Proctor, J. L. McManaman, S. Lucia, S. Chua, and M. Levi. 2005. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes. 54: 2328-2335. (Pubitemid 41134259)
17. Mishra, R., S. N. Emancipator, C. Miller, T. Kern, and M. S. Simonson. 2004. Adipose differentiation-related protein and regulators of lipid homeostasis identified by gene expression profiling in the murine db/db diabetic kidney. Am. J. Physiol. Renal Physiol. 286: F913-F921. (Pubitemid 38508992)
18. Gutwein, P., M. S. Abdel-Bakky, A. Schramme, K. Doberstein, N. Kampfer-Kolb, K. Amann, I. A. Hauser, N. Obermuller, C. Bartel, A. A. Abdel-Aziz, et al. 2009. CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am. J. Pathol. 174: 2061-2072.
19. Rogowski, M. P., M. T. Flowers, A. D. Stamatikos, J. M. Ntambi, and C. M. Paton. 2013. SCD1 activity in muscle increases triglyceride PUFA content, exercise capacity, and PPARdelta expression in mice. J. Lipid Res. 54: 2636-2646.
20. Paton, C. M., and J. M. Ntambi. 2009. Biochemical and physiological function of stearoyl-CoA desaturase. Am. J. Physiol. Endocrinol. Metab. 297: E28-E37.
21. Dobrzyn, P., H. Sampath, A. Dobrzyn, M. Miyazaki, and J. M. Ntambi. 2008. Loss of stearoyl-CoA desaturase 1 inhibits fatty acid oxidation and increases glucose utilization in the heart. Am. J. Physiol. Endocrinol. Metab. 294: E357-E364. (Pubitemid 351231462)
22. Kouroumichakis, I., N. Papanas, P. Zarogoulidis, V. Liakopoulos, E. Maltezos, and D. P. Mikhailidis. 2012. Fibrates: therapeutic potential for diabetic nephropathy? Eur. J. Intern. Med. 23: 309-316.
23. Sun, L., N. Halaihel, W. Zhang, T. Rogers, and M. Levi. 2002. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J. Biol. Chem. 277: 18919-18927. (Pubitemid 34952453)
24. Benhamed, F., P. D. Denechaud, M. Lemoine, C. Robichon, M. Moldes, J. Bertrand-Michel, V. Ratziu, L. Serfaty, C. Housset, J. Capeau, et al. 2012. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J. Clin. Invest. 122: 2176-2194.
25. Urahama, Y., Y. Ohsaki, Y. Fujita, S. Maruyama, Y. Yuzawa, S. Matsuo, and T. Fujimoto. 2008. Lipid droplet-associated proteins protect renal tubular cells from fatty acid-induced apoptosis. Am. J. Pathol. 173: 1286-1294.
26. Lee, H. S., and S. K. Lee. 1993. Intraglomerular lipid deposition in renal disease. Miner. Electrolyte Metab. 19: 144-148.
27. Mayrhofer, C., S. Krieger, N. Huttary, M. W. Chang, J. Grillari, G. Allmaier, and D. Kerjaschki. 2009. Alterations in fatty acid utilization and an impaired antioxidant defense mechanism are early events in podocyte injury: a proteomic analysis. Am. J. Pathol. 174: 1191-1202.
28. Tervaert, T. W., A. L. Mooyaart, K. Amann, A. H. Cohen, H. T. Cook, C. B. Drachenberg, F. Ferrario, A. B. Fogo, M. Haas, E. de Heer, et al. 2010. Pathologic classification of diabetic nephropathy. J. Am. Soc. Nephrol. 21: 556-563.
29. Levey, A. S., L. A. Stevens, C. H. Schmid, Y. L. Zhang, A. F. Castro 3rd, H. I. Feldman, J. W. Kusek, P. Eggers, F. Van Lente, T. Greene, et al. 2009. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150: 604-612.
30. Tachibana, H., D. Ogawa, Y. Matsushita, D. Bruemmer, J. Wada, S. Teshigawara, J. Eguchi, C. Sato-Horiguchi, H. A. Uchida, K. Shikata, et al. 2012. Activation of liver X receptor inhibits osteopontin and ameliorates diabetic nephropathy. J. Am. Soc. Nephrol. 23: 1835-1846.
31. Gudnason, V., T. Zhou, K. Thormar, S. Baehring, J. Cooper, G. Miller, S. E. Humphries, and H. Schuster. 1998. Detection of the low density lipoprotein receptor gene PvuII intron 15 polymorphism using the polymerase chain reaction: association with plasma lipid traits in healthy men and women. Dis. Markers. 13: 209-220. (Pubitemid 28115984)
32. Martini, S., F. Eichinger, V. Nair, and M. Kretzler. 2008. Defining human diabetic nephropathy on the molecular level: integration of transcriptomic profiles with biological knowledge. Rev. Endocr. Metab. Disord. 9: 267-274.
33. Chou, K. M., C. C. Lee, C. H. Chen, and C. Y. Sun. 2013. Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients. Plos One. 8: e54863.
34. Li, S., K. Nagothu, G. Ranganathan, S. M. Ali, B. Shank, N. Gokden, S. Ayyadevara, J. Megyesi, G. Olivecrona, S. S. Chugh, et al. 2012. Reduced kidney lipoprotein lipase and renal tubule triglyceride accumulation in cisplatin-mediated acute kidney injury. Am. J. Physiol. Renal Physiol. 303: F437-F448.
35. Clement, L. C., C. Avila-Casado, C. Mace, E. Soria, W. W. Bakker, S. Kersten, and S. S. Chugh. 2011. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat. Med. 17: 117-122.
36. Feingold, K. R., J. K. Shigenaga, A. S. Cross, A. Moser, and C. Grunfeld. 2012. Angiopoietin like protein 4 expression is decreased in activated macrophages. Biochem. Biophys. Res. Commun. 421: 612-615.
37. Gutwein, P., M. S. Abdel-Bakky, K. Doberstein, A. Schramme, J. Beckmann, L. Schaefer, K. Amann, A. Doller, N. Kämpfer-Kolb, A. A. Abdel-Aziz, et al. 2009. CXCL16 and oxLDL are induced in the onset of diabetic nephropathy. J. Cell. Mol. Med. 13: 3809-3825.
38. Kiss, E., Z. Popovic, J. Bedke, S. Wang, M. Bonrouhi, N. Gretz, P. Stettner, D. Teupser, J. Thiery, S. Porubsky, et al. 2011. Suppression of chronic damage in renal allografts by liver X receptor (LXR) activation relevant contribution of macrophage LXRα. Am. J. Pathol. 179: 92-103.
39. Wang, X. X., T. Jiang, Y. Shen, Y. Caldas, S. Miyazaki-Anzai, H. Santamaria, C. Urbanek, N. Solis, P. Scherzer, L. Lewis, et al. 2010. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes. 59: 2916-2927.
40. Woroniecka, K. I., A. S. Park, D. Mohtat, D. B. Thomas, J. M. Pullman, and K. Susztak. 2011. Transcriptome analysis of human diabetic kidney disease. Diabetes. 60: 2354-2369.
41. Kienesberger, P. C., T. Pulinilkunnil, J. Nagendran, and J. R. Dyck. 2013. Myocardial triacylglycerol metabolism. J. Mol. Cell. Cardiol. 55: 101-110.
42. Nagaya, T., N. Tanaka, T. Suzuki, K. Sano, A. Horiuchi, M. Komatsu, T. Nakajima, T. Nishizawa, S. Joshita, T. Umemura, et al. 2010. Down-regulation of SREBP-1c is associated with the development of burned-out NASH. J. Hepatol. 53: 724-731.
43. Levi, M., X. Wang, and D. Choudhury. 2011. Nuclear hormone receptors as therapeutic targets. Contrib. Nephrol. 170: 209-216.
44. Muroya, Y., O. Ito, R. Rong, K. Takashima, D. Ito, P. Cao, Y. Nakamura, K. Joh, and M. Kohzuki. 2012. Disorder of fatty acid metabolism in the kidney of PAN-induced nephrotic rats. Am. J. Physiol. Renal Physiol. 303: F1070-F1079.
45. Soler, M. J., M. Riera, and D. Batlle. 2012. New experimental models of diabetic nephropathy in mice models of type 2 diabetes: efforts to replicate human nephropathy. Exp. Diabetes Res. 2012: 616313.
46. Feingold, K. R., Y. Wang, A. Moser, J. K. Shigenaga, and C. Grunfeld. 2008. LPS decreases fatty acid oxidation and nuclear hormone receptors in the kidney. J. Lipid Res. 49: 2179-2187.
47. Wang, Y., A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 2005. Downregulation of liver X receptor-alpha in mouse kidney and HK-2 proximal tubular cells by LPS and cytokines. J. Lipid Res. 46: 2377-2387. (Pubitemid 41532526)
48. Kim, M. S., J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2005. Suppression of estrogen-related receptor alpha and medium-chain acyl-coenzyme A dehydrogenase in the acute-phase response. J. Lipid Res. 46: 2282-2288. (Pubitemid 41377480)
49. Feingold, K. R., A. Moser, S. M. Patzek, J. K. Shigenaga, and C. Grunfeld. 2009. Infection decreases fatty acid oxidation and nuclear hormone receptors in the diaphragm. J. Lipid Res. 50: 2055-2063.
50. Feingold, K. R., A. H. Moser, J. K. Shigenaga, S. M. Patzek, and C. Grunfeld. 2008. Inflammation stimulates the expression of PCSK9. Biochem. Biophys. Res. Commun. 374: 341-344.